Insiders Trades
Agenus Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 15 Feb 2024.
Agenus Inc: what insiders have been doing
This page follows insider dealings at Agenus Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Lexington, United States. The group dates from 1994. From 18 October 2025 to 18 October 2026, the disclosure feed for Agenus Inc logged 24 filings by 2 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
No insider has bought Agenus Inc shares on the open market in the past twelve months. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. Section 16 rules allow two business days to file each Form 4.
For context, the typical company on the same exchange (median of 5,812 companies) published 19 filings over the same period, against 24 filings here. The full history, which starts in 2016, counts 2 purchases against no sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 114.2 m USD and net income of -3.1 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
123
Thresholds
n/a
Buy Volume
€319,409
2 ops. · all time
Sell Volume
n/a
n/a
Analyst consensus: bullish or bearish?
Analysts rate Agenus Inc Strong Buy (bullish), based on 3 analysts. Average price target: US$26.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,160 of 24,148 companies
43.5
score / 100
Value41
Quality46
FCF yld-26%
Earn yld-0.0%
EV/EBITDA5.7x
ROE·
Gross mgn30%
Net mgn-0.1%
Debt/EBITDA0.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.43
Analyst consensus
3 analystsStrong buy
US$14.00Target US$26.33(+254%)US$40.00
Income statement
RevenueUS$114.2M
Gross profitUS$33.8M30% margin
EBITDAUS$62.2M54% margin
Net income-US$101k69.3% margin
Valuation
PER (trailing)2.9x
PER (forward)-67.5x
Beta1.32
Balance sheet & cash
Market capUS$335.6M
Total debtUS$55.9M
Free Cash Flow-US$77.2M
Profitability & ownership
ROA12.5%
% insiders6.3%
% institutions46.4%
Last declaration on 2 October 2026
Declarations123 total
4,443 shares@ US$6.8930.0068% mcap15.3% of flowCommon StockSEC:0001193125-26-412039:0
4,852 shares@ US$3.350.0042% mcap0.5% of flowCommon StockSEC:0001193125-26-303047:0
8,547 shares@ US$3.5830.0080% mcap18.0% of flowCommon StockSEC:0001193125-26-297094:0
5,364 sharesCommon StockSEC:0001193125-26-289278:0
4,925 sharesCommon StockSEC:0001193125-26-271889:0
4,644 shares@ US$3.500.0044% mcap0.5% of flowCommon StockSEC:0001193125-26-252375:0
4,540 shares@ US$3.580.0044% mcap0.5% of flowCommon StockSEC:0001193125-26-231046:0
4,233 shares@ US$3.840.0044% mcap0.5% of flowCommon StockSEC:0001193125-26-206908:0
3,403 shares@ US$4.790.0043% mcap0.5% of flowCommon StockSEC:0001193125-26-166818:0
9,228 shares@ US$3.31917.7% of flowCommon StockSEC:0001193125-26-152886:0
4,629 shares@ US$3.330.4% of flowCommon StockSEC:0001193125-26-143765:0
3,983 shares@ US$3.710.0040% mcap0.4% of flowCommon StockSEC:0001193125-26-121840:0
4,994 shares@ US$2.960.4% of flowCommon StockSEC:0001193125-26-098528:0
4,829 shares@ US$3.060.4% of flowCommon StockSEC:0001193125-26-066948:0
5,027 shares@ US$2.940.4% of flowCommon StockSEC:0001193125-26-042772:0
4,562 shares@ US$3.240.4% of flowCommon StockSEC:0001193125-26-022561:0
3,780 shares@ US$3.910.4% of flowCommon StockSEC:0001193125-26-010360:0
7,691 shares@ US$3.98217.4% of flowCommon StockSEC:0001193125-26-002395:0
4,942 shares@ US$3.310.5% of flowCommon StockSEC:0001193125-25-335288:0
4,316 shares@ US$3.790.5% of flowCommon StockSEC:0001193125-25-319186:0
3,587 shares@ US$4.560.5% of flowCommon StockSEC:0001193125-25-303859:0
3,769 shares@ US$4.340.5% of flowCommon StockSEC:0001193125-25-284600:0
4,120 shares@ US$3.970.5% of flowCommon StockSEC:0001193125-25-266875:0
4,216 shares@ US$3.880.5% of flowCommon StockSEC:0001193125-25-245089:0
3,951 shares@ US$4.140.5% of flowCommon StockSEC:0001193125-25-231857:0
25 of 123 declarations
About Agenus Inc
Agenus Inc. (ticker: AGEN) is a clinical-stage biotechnology company listed on the Nasdaq Capital Market in the United States, with principal executive offices at 3 Forbes Road in Lexington, Massachusetts. The company was founded in 1994 by Garo H. Armen, who remains its Chairman and Chief Executive Officer. Agenus’ core mission has long been to broaden the population of patients who can benefit from cancer immunotherapy, and its operating model is built around internal discovery, translational research, clinical development, regulatory capabilities, and selective collaborations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098972/000119312526197554/agen-ars-2025.pdf))
From an industry perspective, Agenus is not yet a commercial-stage pharma company with a mature marketed franchise; rather, it is a biotech focused on advancing next-generation immuno-oncology assets. Its lead clinical program is botensilimab (BOT, AGEN1181), an Fc-enhanced anti-CTLA-4 antibody, typically paired with balstilimab (BAL), a PD-1 inhibitor. That BOT/BAL combination is the centerpiece of the company’s strategy and is being studied across multiple solid-tumor settings, especially microsatellite-stable metastatic colorectal cancer, but also pancreatic cancer, melanoma, lung cancer and other tumor types. Agenus also has a broader pipeline including AGEN2373, AGEN1571, AGEN1777, AGEN1423 and AGEN1949, which gives the company a wider scientific footprint than many single-asset biotech peers. ([agenusbio.com](https://agenusbio.com/pipeline/))
Read moreShow less
Agenus competes in one of the most crowded and capital-intensive segments of biotech. The company explicitly notes competition from large pharmaceutical companies and emerging biotechnology peers across PD-1/PD-L1, CTLA-4, LAG-3, TIM-3, CD73, CD137 and TIGIT programs. In other words, the investment case hinges less on current revenues and more on clinical validation, durability of response, and the ability to secure partnerships or future commercialization pathways. BOT/BAL is therefore the key value driver, while the rest of the pipeline provides optionality. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098972/000119312526197554/agen-ars-2025.pdf))
Geographically, Agenus is primarily a United States company, with manufacturing, R&D and corporate activities in Lexington, Massachusetts, plus corporate office space in New York and a California facility for cGMP manufacturing development. It also works through a global clinical footprint and multiple external collaborations. Recent highlights include management’s strategic realignment announced in late 2024, which prioritized the BOT/BAL program and paused certain non-core activities, as well as continued 2025-2026 updates on clinical data, the phase III BATTMAN study, and a strategic collaboration with Zydus Lifesciences aimed at advancing BOT/BAL and strengthening U.S. manufacturing readiness. For investors, AGEN remains a high-risk, event-driven biotech whose valuation is likely to be driven by trial readouts, partnership execution, and balance-sheet considerations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098972/000119312526197554/agen-ars-2025.pdf))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
